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Summary A multicentre randomised phase III trial in chemotherapy-naive patients with advanced non-small-
cell lung cancer (NSCLC) was undertaken to compare the therapeutic activity and toxicity of a cisplatin/
carboplatin-etoposide-vinorelbine combination with that of a cisplatin-etoposide regimen. Patients with
advanced (stage IIIB-IV) NSCLC were randomised, after stratification for stage (IIIB-IV) and performance
status (0-1 and 2), to receive either (A) CDDP 40 mgm 2+VP16 100mgm-2 on days 1-3 as standard
treatment or (B) CBDCA 250 mgm-2 on day 1 + CDDP 30 mgm-2 on days 2 and 3 + VP16 100 mgm-2
on days 1-3 + NVB 30 mgm-2 on day 1. Therapy was recycled on day 29 in both arms. We hypothesised a
15% minimum increment in the response rate with the experimental regimen over the 25% expected activity
rate of the standard regimen. A two-stage design was chosen, which permitted the early termination of the trial
(after the accrual of 52 patients in each arm) if the difference in response rates between the two regimens was
less than 3% at the end of the first stage. A total of 112 patients (arm A = 57, arm B =55) were enrolled in the
study (53 with stage IIIB and 59 with stage IV), of which 105 eligible patients were evaluable for response on
an 'intention to treat' basis. Seven patients were excluded because they did not fulfil the inclusion criteria.
Fifteen responses were observed in arm A (28%, 95% CI = 17-42) and 13 (one complete) in arm B (25%, 95%
CI= 13 -37). On multivariate logistic analysis, treatment did not affect the response rate, while stage IV and
performance status 2 were significantly associated with a lower probability of response. Median survivals were
similar in the two arms (31 vs 27 weeks). The experimental regimen was associated with an extremely poor
median survival in patients with poor performance status (21 weeks). On Cox analysis, treatment failed to show
a significant impact on survival: stage IV (relative risk= 1.6, CI = 1.0 -2.6, P=0.036) was the only prognostic
variable significantly associated with a worse survival outcome and, although poor performance status
adversely affected survival, this effect did not reach the level of statistical significance (relative risk =1.6,
CI=0.98-2.5; P= 0.063). There were no significant differences in non-haematological toxicities between the
two arms, although three patients in the control arm had to discontinue the treatment because of the
persistence of severe nephrotoxicity (two patients) or neurotoxicity (one patient). In contrast, a significant
increase in both neutropenia and thrombocytopenia was observed in the experimental arm. Four treatment-
related deaths were registered in arm B (two due to neutropenic sepsis, one to myocardial failure and one to
acute renal failure) compared with one toxic death (acute renal failure) in arm A. In view of these results, the
trial was stopped and the null hypothesis (< 15% increase in response rate with the experimental regimen) has
been accepted. Therefore, our combination does not deserve further evalution as first-line treatment in
advanced NSCLC patients. As our data suggest that an aggressive chemotherapy might have a negative impact
on survival of patients with poor performance status, trials to evaluate the activity of new regimens should be
conducted separately for each subset of patients with different performance status.
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Lung cancer remains the leading cause of cancer deaths in
Western countries (Boring et al., 1992). Currently, only a few
chemotherapeutic agents have shown a clear activity in
patients with non-small-cell lung cancer (NSCLC) (Ihde,
1992). Nevertheless, the role of chemotherapy in the
advanced disease has recently been emphasised: a meta-
analysis of 11 randomised trials showed a clear although
modest prolongation of survival in patients receiving
cisplatin-based chemotherapy compared with those who
received only best supportive care (Grilli et al., 1993).
In spite of the large number of trials performed, the best
combination including cisplatin (CDDP) has not yet been
defined. The combination of CDDP with etoposide (VP16) is
one of the most widely used in view of its good therapeutic
index. A recent review reported a cumulative response rate of
27% after CDDP-VP16 administration in more than 1500
patients with advanced NSCLC (Faulds, 1992). Three-drug
regimens, consisting of a combination of CDDP and
mitomycin with vinca alkaloids or ifosfamide (MVP or
MIP) are able to achieve a higher response-rate than the
CDDP-VP16 combination (Bunn, 1989), but their super-
iority in terms of survival had not until recently been
demonstrated in clinical randomised trials (Crino' et al.,
1995). A contemporary trial has yielded conflicting results,
only partly explainable by differences in dosage and schedule
(Ardizzoni et al., 1995).
This issue concerning the optimum CDDP dosage is of
great relevance in the treatment of NSCLC. A meta-analysis
of chemotherapy trials in more than 6247 patients
demonstrated a significant correlation between response rate
and CDDP dose, with improved activity of high
( 1l00mg m-2) as opposed to low doses (<lO1 mg m-2)
(Donnadieu et al., 1991). However, at doses )100 mg m-2,
CDDP can cause significant neurotoxicity and nephrotoxi-
city, which may result in discontinuation of its administra-
tion, or in early deaths as a result of acute renal failure. In
view of this, the partial substitution of CDDP with
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carboplatin (CBDCA), a CDDP analogue with a better
toxicological profile, has been advocated in an attempt to
administer a standard or even higher dose of platinum
therapy with acceptable toxicity. In a EORTC study, patients
were randomised to receive either CDDP alone at the dose of
120 mg m-2 on day 1 or CDDP 30 mg m-2 on days 2 and 3
plus CBDCA 200 mg m-2 on day 1. The response rates were
23% and 22%, respectively, but the combined treatment
showed a lower toxicity (Sculier et al., 1994). The
combination of CDDP and CBDCA has also been tested in
addition to VP16 with promising results. A 41% response
rate was reported in a phase I/II study employing CDDP
80 mg m-2 on day 1, VP16 80 mg m-2 on days 1-3 and
CBDCA 280 mg m-2 on day 1 (Tsuchiya et al., 1993).
Another trial (Sakuray et al., 1993) showed an even higher
response rate (57%) in spite of the lower dosages of CDDP
(50 mg m-2) and CBDCA (200 mg m-2) used in combination
with VP16.
Numerous molecules, other than CDDP and VP16, have
been tested in this last decade in an attempt to improve the
efficacy of combination chemotherapy against NSCLC.
Vinorelbine (VNR) seems one of the most interesting in
view of its good activity rate as single agent (Depierre et al.,
1989) and of the synergism shown in vitro with both cisplatin
and etoposide (Cros et al., 1989). In a recent three-arm
randomised trial (Le Chevalier et al., 1994), the combination
of CDDP and VNR achieved a significantly higher response
rate and better survival than the cisplatin-vindesine regimen.
The addition of VNR to the standard CDDP-VP16
combination was tested with promising results (Jacoulet et
al., 1991).
Based on these considerations, we started the present
phase III randomised trial. This study aimed to evaluate
whether the addition of VNR could significantly improve
the therapeutic activity of the CDDP-VP16 combination.
In addition, CDDP was partly replaced with CBDCA in
the experimental arm, in order to decrease the incidence
and severity of CDDP-induced nephrotoxicity and neuro-
toxicity.
Patients and methods
Eligibility criteria
Patients were eligible if they fulfilled the following criteria:
histologically or cytologically proven diagnosis of NSCLC;
advanced measurable disease (stage IIIB or IV); age <75
years; ECOG performance status <2; no previous che-
motherapy; life expectancy . 3 months. Furthermore,
patients had to have adequate bone marrow reserve (WBC
>4000 mm-', platelets > 120 000 mm-3 and Hb >11 g dl -
and normal liver (serum bilirubin < 1.25 mg dl-') and renal
function (serum creatinine < 1.25 mg dl- ' calculated creati-
nine clearance >60 ml min- ). Patients with congestive heart
failure, angina, serious arrhythmias or recent myocardial
infarction, uncontrolled infectious or metabolic diseases were
excluded. Each patient gave informed consent to participate
in this trial, which was approved by the Ethics Committee for
Biological Research of the National Tumor Institute of
Naples.
Work-up procedures
Diagnosis was made by a biopsy performed during fibreoptic
bronchoscopy, or by a transthoracic fine-needle aspiration
biopsy in cases of peripheral mass. At entry, a complete
medical history was obtained, clinical and physical examina-
tion (including assessment of weight loss in the last 6 months
and ofperformance status) was performed, and the following
laboratory tests were carried out: WBC (total and differ-
ential), RBC and platelets counts, Hb, glutamic oxaloacetic
transaminase (GOT) and glutamic pyruvic transaminase
(GPT), alkaline phosphatase (ALP), gamma-glutamyl trans-
ferase (y-GT), lactate dehydrogenase (LDH), bilirubin,
glucose, blood urea nitrogen (BUN), uric acid, creatinine
and creatinine clearance, total protein and albumin,
carcinoembryonic antigen (CEA), tissue polypeptide antigen
(TPA), neuron-specific enolase (NSE), Cyfra-21.1, sodium,
potassium, calcium, phosphorus and magnesium. Extent of
disease was evaluated by means of the following instrumental
tests: chest radiograph, computed tomographic (CT) scan of
thorax and upper abdomen, liver ultrasound scan and bone
scintigraphy. When necessary, a brain CT scan was
performed to rule out cerebral metastases. Bone radiography
was limited to suspicious areas revealed by radionuclide scan.
Physical examination and blood count were performed
weekly to assess nadir haematological toxicity and the non-
haematological toxicity behaviour. During each cycle patients
underwent physical examination, together with blood count
and chemistry. At restaging, the evaluation of all measurable
lesions was performed using the same procedures employed
before the beginning of therapy.
Treatment
All patients were stratified according to stage (IIIB vs IV) and
performance status (0-1 vs 2) and randomly allocated to one
of two arms ofcombination chemotherapy: patients in arm A
received both CDDP, 40 mg m-2 i.v., and VP16, 100 mg m-2
i.v., on days 1-3; patients in arm B were treated with
CBDCA, 250 mg m-2 i.v., on day 1, CDDP 30 mg m 2, on
days 2 and 3, VP16 100 mg m 2 i.v., on days 1-3, and VNR,
30 mg m2, on day 1. CDDP and CBDCA were administered
in 250 ml of normal saline over 30 min. VP16 diluted in
250 ml of normal saline was administered over 45 min. VNR
was diluted in 100 ml of normal saline and administered over
10 min. A short-term hydration (2 1 of normal saline plus
20 mequiv. potassium chloride over 4 h and antiemetic
prophylaxis (anti-HT3 receptors plus dexamethasone) were
given in both arms concomitantly with cisplatin administra-
tion. Courses were repeated every 4 weeks in both arms
provided that there was a complete bone marrow recovery
from previous treatment (neutrophils >2000 and platelets
> 100 000). Dosages of all drugs were reduced by 25% if
grade 4 neutropenia or thrombocytopenia occurred at nadir,
or if grade >2 major organ toxicity, even if reversible, was
observed or if grade 1 neutropenia or thrombocytopenia
persisted after a 1 week delay. Therapy was delayed for 1
week if the neutrophil count was <2000 mm-', the platelet
count was <100 000 mm-3 or the Hb level was <8 g dl-'
(in this case a blood transfusion was performed to increase
the Hb level to up to 8 g dl-1 or more). If grade > 1
neutropenia or thrombocytopenia persisted for 2 weeks or
more, after the scheduled time of recycling, treatment was
discontinued. Treatment was also discontinued if there was
persistence of >WHO grade 2 neurological or renal
toxicities, or if severe hearing loss occurred. Furthermore,
CDDP dosage was reduced by 50% if the serum creatinine
level increased above 1.5 mg dl-', whereas it was discon-
tinued if it increased above 2 mg dl-'.
Evaluation of response and toxicity
Patients were fully reassessed for response to therapy after
three courses according to WHO criteria (Miller et al., 1981).
Responses were blindly reviewed by a central review board
consisting of two radiologists and two oncologists. In cases of
complete or partial response, three further courses were
administered. Patients with no change after three courses, or
progressive disease at any time, were withdrawn from the
treatment and usually had no further cytotoxic drugs but
only supportive therapy or local irradiation to relieve
symptoms.
All patients receiving fewer than three courses because of
worsening of clinical status or early death, as well as those
who had treatment suspension due to toxicity or refusal, were
included in an intention-to-treat analysis of the total
population and considered treatment failures. Toxicity oftherapy was scored according to WHO criteria (Miller et al.,
1981). It was analysed with respect to the number of patients
treated and the number of cycles administered.
Study design and statistical analysis
A centralised telephone call procedure was used to assign
patients randomly to treatment arm on the basis of a
computer-generated list, stratified according to stage and
performance status. The aim of the trial was to determine
whether the experimental treatment had a 15% higher
activity than the control treatment. The average activity
rate of standard CDDP-VP16 regimen was taken to be 25%.
The sample size was established by using a two-stage
optimal design for phase III trials with binary response (Thall
et al., 1988). This design permitted an early acceptance of the
null hypothesis after the first stage (so minimising the
expected number of patients to be accrued) if the
experimental combination did not have a substantially
higher therapeutic activity than the standard regimen.
Setting the errors alpha and beta at 5% and 20%
respectively, 52 patients for each arm had to be randomised
in the first stage. If actual response rate observed in the
experimental arm did not exceed that of the control arm by
at least 3%, accrual was stopped and the experimental
combination rejected. In the opposite case, 75 additional
patients had to be accrued in each arm. This stage 1 stopping
rule was specified by the equation Pe-P >y1(2pc.qcln1)"2,
Pe-Pc defined the difference in response rate observed at the
end of the first stage, p, is the chosen activity rate for the
control arm, qc= 1 -p, (25% and 75% respectively), nI is the
sample size at the first stage (52 patients) and y1 expresses the
minimum value of z at first stage to reject the null hypothesis
and continue the accrual.
Fisher's exact test was applied for comparison between
group frequencies (Fisher et al., 1963). The main pretreat-
ment variables-performance status (0-1 vs 2), stage (IIIB vs
IV), histology (squamous vs others), weight loss > 5 kg (yes
vs no) and age (<65 vs ) 65)-together with treatment type
were included in a logistic linear model to determine the
effect of treatment on response rate when adjusted for the
main prognostic features (Fisher, 1950). Survival curves were
plotted using the product-limiting method reported by
CDDP/CBDCA+VP16+vinorelbine in advanced NSCLC
P Comella et at t
1807
Kaplan et al. (1958), and their comparisons were made
using the log-rank test (Mantel, 1966). The Cox proportional
hazard model (Cox, 1972) was used to evaluate the effect of
treatment on survival after adjustment for the main
pretreatment variables. The assumption of proportional
hazard of death over time was verified before performing
the analyses and met by all covariates. Adjusted relative risks
were calculated as antilogarithms of the regression coefficient.
All these analyses were performed using the Systat package
(Wilkinson, 1988).
Results
Patient demographics
Between March 1993 and June 1995, a total of 112 patients
were enrolled into the first stage of the trial. Among them,
seven patients were considered ineligible because they had
stage IIIA disease (two cases) or did not meet the
haematological (three cases) or performance status require-
ments (two cases). Characteristics of eligible patients are
reported in Table I. Nearly 90% of patients were men. More
than 40% ofpatients had poor performance status, and more
than half of patients had stage IV disease (with multiple
metastatic sites in half of the cases). No significant differences
between the two arms of treatment were observed with
respect to age, sex, stage, performance status or weight loss.
A significant (Fisher's P=0.02) imbalance was observed in
distribution of histological subtypes (more patients in arm B
had non-squamous histology), as the patients were not
stratified according to their histotype. A total of 284 courses
were delivered (148 and 136 in arm A and B respectively).
The median number of courses delivered was three (range I -
6) in both arms.
Analysis of activity
All the 105 eligible patients were included in the response
analysis (Table II). Toxic deaths (5), withdrawal for toxicity
(4), lost to follow-up (3), and refusal to continue treatment
(1) were all considered as failures on an 'intention-to-treat'
basis. In arm A, we registered 15 partial responses out of 53
eligible patients, for an overall activity rate of 28% (95%
Table I Main characteristics of patients
Characteristics
Total entered patients
Eligible patients
Men
Women
Median age
Range
Age>65 years
Performance status
0-1
2
Weight loss > 5kg
Yes
No
Histology
Squamous cell
Adenocarcinoma
Large cell/undifferentiated
Unclassified
Stage
Arm A
No. (%)
57
53
47 (89)
6 (11)
59.5
35 -72
12 (23)
31 (58)
22 (42)
22 (41.5)
31 (58.5)
34 (64)-
12 (23)
5 (9)
2 (4)
IIIB 25 (47)
IV 28 (53)
Multiple metastases 22 (79)
aSquamous vs others: P=0.02 (Fisher's exact test).
Arm B
No. (%)
55
52
46 (88.5)
6 (11.5)
60.5
40-73
19 (36)
29 (56)
23 (44)
19 (36.5)
33 (63.5)
22 (42)
26 (50)
2 (4)
2 (4)
23 (44)
29 (56)
24 (83)
Total
No. (%)
112
105
93 (88.5)
12 (11.5)
59.5
35 -73
31 (29)
60 (57)
45 (43)
41 (39)
64 (61)
56 (53)
38 (36)
7 (7)
4 (4)
48 (46)
57 (54)
46 (81)CDDP/CBDCA+VP16+vinorelbine in advanced NSCLC
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CI= 17-42%). In arm B, one complete response and 12
partial responses were observed for an overall activity rate of
25% (95% CI=13-37%). No change and disease progres-
sion were similarly distributed in the two groups. In view of
the lower (although not statistically significant) response rate
observed in the experimental arm compared with standard
treatment at this first-stage analysis, the accrual was stopped,
and the null hypothesis was accepted.
In a descriptive analysis, stage IIIB, performance status
0- 1, age <65 and weight loss < 5 kg were associated with a
higher response rate in the whole population, although the
correlation was statistically significant only for stage IIIB
(Table III). Histology did not show any meaningful
correlation with response rate in the whole population.
However, as there was an imbalance in histotype distribution
between the treatment groups, we performed a Mantel-
Haenszel chi-square test, which showed that treatment did
not significantly affect the probability of response (P=0.7),
even after adjustment for histology (squamous vs others).
In addition, on multiple logistic analysis, the treatment
failed to affect the response rate significantly. Among the
pretreatment features, stage IIIB [regression coeffi-
cient+s.e. =0.98 +0.47; relative risk = 2.7 (CI 1.0-6.8);
P=0.037] and performance status 0- 1 [regression coeffi-
cient+s.e.= 1.04+0.52; relative risk=2.8 (CI 1.0-8.0);
P=0.046] were the only parameters independently predictive
of a higher response rate.
Figure 1 reports the actuarial overall survival curves of
patients in the two arms of the trial. As of the end of
December 1995, the median potential follow-up was 86 weeks
for arm A and 82 weeks for arm B. A total of 89 deaths had
occurred. Eight patients in each arm were still alive.
Table II Response
Arm A Arm B
No. (%) No. (0)
Total eligible patients 53 52
Early progression or death 6 (11) 9 (17)
Toxic death 1 (2) 4 (8)
Withdrawn for toxicity 3 (6) 1 (2)
Lost to follow-up 2 (4) 1 (2)
Refused therapy 0 1 (2)
Assessed after three courses 41 (77) 36 (69)
Overall responses 15 (28) 13a (25)
No change 14 (26) 11(21)
Progressive disease 12 (23) 12 (23)
aOne complete.
Median survival time was 31 weeks in arm A and 27 weeks
in arm B, and the difference was not statistically significant.
Using multivariate Cox analysis, the type of treatment failed
to show a significant impact on survival, while the outcome
of the patients was significantly affected by stage and
performance status (Table IV). The experimental regimen
showed a highly different effect in the two subgroups defined
on the basis of performance status. Median survival was 46
weeks in patients with performance status 0-1 and 21 weeks
in those with performance status 2. A particularly high risk
of early death was observed in the latter group, as confirmed
by the evidence of only a 54% 3 month survival in this
group. To the contrary, a different performance status did
not translate into a clearly different median survival in the
control arm (Figure 2).
Toxicity
Myelosuppression was the most frequent and limiting side-
effect (Table V). Both neutropenia and thrombocytopenia
were significantly more frequent in the experimental arm and
two treatment-related deaths as a result of neutropenic sepsis
occurred in this arm, compared with no events in the control
arm. One patient in the experimental arm had to suspend
therapy because of persistent neutropenia. Two patients
required platelet transfusion in the experimental arm, but
no clinically relevant haemorrhagic episodes were encoun-
tered. Grade 4 non-haematological toxicity never occurred,
except for vomiting (Table VI). Nephrotoxicity and
ototoxicity were slightly less frequent in arm B, but this
improvement was not statistically significant. One patient in
each arm died as a consequence of an acute renal failure.
Finally, one additional patient in arm B died because of acute
myocardial failure. Three patients in arm A discontinued
treatment because of persistent nephrotoxicity (two patients)
or neurotoxicity (one patient), while only one patient
discontinued treatment in arm B because of persistent
nephrotoxicity. The actual delivered dose intensity, during
the first three courses, was 91% in arm A and 86% in arm B.
Taking into account all delivered courses, the mean relative
dose intensity was 89% in arm A (CDDP 87%, VP-16 91%)
and 83% in arm B (CDDP 81%, CBDCA, VNR and VP-16
84%).
Discussion
An interesting response rate (33%) was reported in a pilot
study testing the addition of vinorelbine to the standard
cisplatin-etoposide combination, in a population with
Table III Responses according to the main patient characteristics
Characteristics
Men
Women
Age
<65 years
>65 years
Performance status
0-1
2
Weight loss >5kg
No
Yes
Histology
Squamous
Other
Stage
IIIB
IV
ap= 0.016. bp=0.019.
Arm A (%) Arm B (%) Total (%)
13/47 (28) 10/46 (22) 23/93 (25)
2/6 (33) 3/6 (50) 5/12 (42)
12/41 (29) 11/33 (33) 23/74 (31)
3/12 (25) 2/19 (10) 5/31 (16)
9/31 (29) 11/29 (38) 20/60 (33)
6/22 (27) 2/23 (9)- 8/45 (18)
10/31 (32) 10/33 (30) 20/64 (31)
5/22 (23) 3/19 (16) 8/41 (19)
10/34 (29) 4/22 (18) 14/56 (25)
5/19 (26) 9/30 (30) 14/49 (29)
10/25 (40) 8/23 (35) 18/48 (37)
5/28 (18) 5/29 (17) 10/57 (17)b
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Figure 1 Overall survival according to treatment. - - -, Arm A
(53 patients), failures=45; , Arm B (52 patients), failures=44.
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Table IV Cox survival analysis in all patients (After stratification for treatment)
Median survival Regression Relative risk
Covariate (weeks) coefficient+ s.e. P-value (95% CI)
Age 32 0.191 +0.269 0.484 1.2 (0.7-2.0)
<65 27
., 65
Performance status
0- 1 37 0.432+0.242 0.075 1.5 (0.96-2.5)
2 26
Stage
IIIB 40 0.503+0.235 0.031 1.6 (1.0-2.6)
IV 26
Weight loss>5kg
No 37 0.425±0.281 0.134 1.5 (0.9-2.7)
Yes 27
Histology
Squamous 29 -0.173+0.247 0.484 0.8 (0.5-1.4)
Others 32
.
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Figure 2 Overall survival according to performance status (PS)
and treatment. Arm A: , PS 0-1 (31 patients); - - -, PS 2 (22
patients); arm B: -F]-, PS 0-1 (29 patients); - -L- -, PS 2 (23
patients). -O- vs - -O- -, P=0.023.
particularly poor prognostic factors (Jacoulet et al., 1991).
Moreover, in this study, the response rate increased to over
40% in younger patients or in those with better performance
status.
We also previously evaluated the cisplatin -etoposide -
vinorelbine regimen in a phase 1/11 study, obtaining a very
promising response rate (42%) (Comella et al., 1994). In this
trial, we tested the administration of vinorelbine both at the
dose of 30 mg m-2 on day and at the dose of 25 mg m-2
on days 1 and 8, however this latter schedule was associated
with an unacceptable incidence of grade 3-4 neutropenia.
The present randomised study aimed at evaluating whether
this three-drug combination could provide a significant
therapeutic advantage (an increase in response rate of at
least 15%) over the standard CDDP-VP16 regimen. We
decided to partly replace CDDP with CBDCA in the
experimental arm in view of the proven similar activity of
the two drugs and the better tolerance of CBDCA.
Our results clearly show that this experimental regimen does
not substantially improve the prognosis of advanced NSCLC
patients, in terms ofboth response rate and overall survival. We
stopped the trial after the first stage because the response rate
observed in the experimental arm was even lower than that
achieved in the control group, hence we did not fulfil the
minimum condition required by our study design (a >3%
increase in response rate in the experimental arm) to complete
the enrolment. A high number of early treatment failures
occurred in the experimental arm, owing mainly to a higher
incidence and severity of both neutropenia and thrombocyto-
penia. It is worth noting that the majority of these early
treatment failures occurred in patients with poor performance
status. A 9% response rate was observed in this subgroup,
while the level oftherapeutical activity was quite acceptable in
patients with good or intermediate performance status.
Survival was also strongly affected by performance status in
this arm (46 week vs 21 week median survival).
We can argue that in poor-performance patients a more
chemoresistant tumour and a lower host tolerance to
aggressive therapy may coexist. The addition of a single
dose of vinorelbine might not have been enough to increase
the cell kill of chemotherapy, but might have significantly
increased the toxicity of the treatment, which translated into
more frequent early treatment failures. In the study of
Jacoulet et al. (1991) the addition of vinorelbine to CDDP-
VP16 was also associated with a high number of early
treatment failures, especially in poor-performance or elderly
patients. However, the frequency of severe neutropenia
observed in the present study was unexpectedly higher than
that observed in our previous pilot study. Hence, we cannot
exclude the possibility that the partial replacement of CDDP
with CBDCA could also have had a role in impairing the
tolerance of the experimental arm. On the other hand, the
good response rate and survival observed in patients with
better performance status, together with a lower incidence of
severe myelosuppression, may be explained by the coexistence
of a more chemosensitive tumour and a better compliance to
aggressive treatments in these patients.
The negative impact of a multidrug treatment with the
addition of mitomycin to CDDP-VP16 on poor-prognosis
NSCLC patients was also claimed by the Umbria Group
(Crino' et al., 1990) to explain the unsatisfactory results
reported in the past. In fact, a higher fraction (about 50%) of
patients with poor performance status was enrolled in that
study as compared with a significantly lower percentage
(about 15%) included in a more recent trial carried out by
the same authors (Crino' et al., 1995), which demonstrated a
significant increase in both response rate and overall survival
with three-drug combinations.
In our study, the CDDP-VP16 treatment showed an
acceptable level of activity as regards both response rate
(28%) and median survival (31 weeks). Although the smaller
size of our study population renders the 95% confidence
interval of response rate quite wide, we think that the true
level of activity of the CDDP-VP16 combination probably
ranges between a 25% and 30% response rate. The CDDP-
VP16 regimen, recycled every 4 weeks, showed a manageable
toxicity even in poor-performance status patients, and this
resulted in a good therapuetic activity also in this group. On
the other hand, our data confirm that this combination isA CDDP/CBDCA+VP16+vinorelbine in advanced NSCLC
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Table V Acute haematological toxicity
WHO Arm A' Arm Bb
Toxicity grade n (%) n (%) P-value
Neutropenia 0 106 (72) 62 (45.6) 0.000006
1 21 (14) 24 (17.6)
2 13 (8.7) 27 (19.8)
3 7 (4.7) 16 (11.8)
4 1 (0.6) 7 (5.2)
Thrombocytopenia 0 132 (89.2) 92 (67.5) 0.000007
1 6 (4) 13 (9.5)
2 8 (5.4) 19 (14)
3 2 (1.4) 7 (5.1)
4 0 5 (4)
Anaemia 0 89 (60.2) 70 (51.5) 0.04
1 27 (18.2) 26 (19.1)
2 24 (16.2) 33 (24.3)
3 8 (5.4) 5 (3.7)
4 0 2 (1.4)
aNumber ofcourses 148. bNumber ofcourses= 136. P-value expresses the comparison between toxicities ofany grade in
the two arms.
Table VI Acute non-haematological toxicity
Toxicity
Nausea/vomiting
Nephrotoxicity
Diarrhoea
Neurotoxicity
Ototoxicity
WHO
grade
0
1
2
3
4
0
1
2
3
4
0
1
2
3
4
0
2
3
4
0
1
2
3
4
Arm A'
n (%)
51 (34.5)
37 (25)
45 (30.5)
9 (6)
6 (4)
133 (90)
11 (7)
3 (2)
1 (1)
0
136 (92)
8 (5)
4 (3)
0
0
136 (92)
8 (5)
4 (3)
0
0
138 (93)
7 (4.9)
2 (1.4)
1 (0.7)
0
Arm Bb
n (%)
43 (32)
35 (26)
41 (30)
11 (8)
6 (4)
127 (93)
5 (4)
2 (1.5)
2 (1.5)
0
125 (92)
7 (5.2)
3 (2.1)
1 (0.7)
0
125 (92)
8 (5.9)
2 (1.4)
1 (0.7)
0
130 (95.8)
5 (3.5)
1 (0.7)
0
0
aNumber ofcourses = 148. bNumber ofcourses = 136.
clearly less active than more aggressive regimens in the
presence of metastatic disease. The unsatisfactory therapeutic
activity of CDDP-VP16 in patients with stage IV NSCLC
has been particularly emphasised by the GOIRC results,
which reported a significant therapeutic advantage in this
group only with aggressive three-drug regimens.
Our trial seems to confirm that it is not clear whether
'more is better' in NSCLC patients, at least not in all
patients. Also, a careful analysis of the literature does not yet
enable us to draw any definitive conclusion on this issue. The
increase in response rate and survival recently reported with
MVP and MIP (Crino' et al., 1995) is very modest, and may
not concern all patients with advanced NSCLC as about 85%
of patients had good or intermediate performance status in
that study. Moreover, both the MVP and MIP regimens
failed to show a clear therapeutic advantage over less
aggressive two-drug regimens in other randomised trials
(Weick et al., 1991; Bonomi et al., 1989). The 40% response
rate and the 10 month median survival reported by Crino' et
al., in their substantially good-prognosis population, does not
represent a sufficiently satisfactory result to recommend the
three-drug cisplatin regimens as a gold-standard therapeutic
approach in all advanced NSCLC patients. Therefore, further
efforts must be made in the near future to improve
substantially the fate of these patients. Recent clinical trials
have demonstrated that a higher than 50% response rate,
with a median survival often exceeding 1 year, can be
achieved with addition of platin compounds to the newest
molecules, i.e. gemcitabine and taxanes (Crino' et al., 1995;
Zalcberg et al., 1995; Langer et al., 1995).
In future trials, however, more attention should be paid to
the impact of the treatment on survival. Most of the clinical
randomised trials conducted in the last decade have failed to
show a significant difference in overall survival, in spite of the
large differences in response rates. This was mainly because
of the short duration of response in most cases, so that even
a 20% increase in response rate resulted in a negligible
prolongation of median survival of the whole population. In
addition, potential survival improvement related to the
increased number of tumour regressions might have been
hidden in some cases by the higher number of early deaths
due to the higher toxicity. Therefore, in our opinion, a
definite reduction of the death risk should be the main
parameter for determining sample size in future trials.
Furthermore, a careful analysis of prognostic factors such
as stage of disease, performance status, etc., is mandatory to
avoid a misinterpretation of results. Many randomised trials
in the past gave inconclusive results because a clear differnece
in response rate between the treatments existed only in a
subset of the study population, but the size of this fraction
was not large enough to permit its statistical detection.
In view of this, we think that separate randomised trials
should be carried out, in advancedNSCLC, to determine which
is the best therapeutic approach in each subset of patients.
Patients with only locally advanced disease should be evaluated
separately, in view of both the expected better prognosis and
the possible positive impact of the addition of radiotherapy.
Among patients with metastatic disease, two conceptually
different therapeutic strategies should be tested. Firstly,
maximum effort should be devoted to increasing dose intensity
andcombining new drugs with differentmechanisms inpatients
with good or intermediate performance status and age <70, in
view of their better tolerance to treatment and the predictable
higher sensitivity of the tumour. In accordance with this
consideration, in some recent trials the aggressive new
combinations have been tested only in patients with
performance status 0-1 (Crino' et al., 1995; Langer et al.,
1995). Secondly, more attention should be paid to the host
status in the elderly or poor performance status patients. A less
toxic chemotherapy, combined with non-cytotoxic drugsCDDP/CBDCA+VP16+vinorelbine in advanced NSCLC
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(biological response modifiers, lonidamine, melatonine,
differentiating agents, etc.) could be the best therapeutic
approach in these patients. This approach is probably unable
to obtain a dramatic tumour shrinkage in the majority of
patients; however, it may be able to delay the progression ofthe
tumour at the price ofmild toxicity, resulting in either a longer
survival or a better quality oflife.
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